Anneke van Sloten
Adult Health · Spokane, WANPI 1285016139
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novo Nordisk at 26.2% of the total. 2025 is the largest year on record at $690, 4.1 times the $169 reported in 2021.
Across 77 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$520
- Medtronic$296
- Dexcom, Inc.$186
- Tandem Diabetes Care, Inc.$154
- Sanofi-aventis U.S. LLC$128
- Mannkind Corporation$111
- plus $590 from 16 others
What the payments were for
- Food & beverage$1,984100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $520 |
| Medtronic | 5 | $296 |
| Dexcom, Inc. | 4 | $186 |
| Tandem Diabetes Care, Inc. | 3 | $154 |
| Sanofi-aventis U.S. LLC | 2 | $128 |
| Mannkind Corporation | 5 | $111 |
| Lilly USA, LLC | 6 | $102 |
| Boehringer Ingelheim | 3 | $61 |
| Nevro Corp. | 2 | $51 |
| Recordati_rare_diseases_inc. | 2 | $43 |
| Amgen | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Sequel Med Tech, LLC | 2 | $41 |
| Corcept Therapeutics | 2 | $37 |
| Chiesi USA, Inc. | 1 | $29 |
| BETA Bionics, Inc. | 1 | $28 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Novartis | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Insulet Corporation | 1 | $18 |
| Calliditas Therapeutics US Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,984 in reported general payments places this provider in the 85th percentile of 252 adult health providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 246 | $344,847 |
| MounjaroTirzepatide | 220 | $266,079 |
| JardianceEmpagliflozin | 197 | $230,077 |
| TrulicityDulaglutide | 133 | $190,802 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 102 | $158,500 |
| Humalog Kwikpen U-200Insulin Lispro | 42 | $106,808 |
| Tresiba Flextouch U-200Insulin Degludec | 81 | $91,455 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 37 | $91,139 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $75,601 |
| Tresiba Flextouch U-100Insulin Degludec | 82 | $71,609 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 77 | $71,506 |
| FarxigaDapagliflozin Propanediol | 24 | $35,912 |
| Humalog Kwikpen U-100Insulin Lispro | 109 | $34,670 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 26 | $33,666 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 53 | $32,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $102 | $485,109517 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $520 | $380,677307 claims |
| Boehringer IngelheimJardiance, Tradjenta | $61 | $249,889224 claims |
| AstraZenecaFarxiga | $19 | $35,91224 claims |
| Sanofi-aventis U.S. LLCLantus | $128 | $1,71314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 252 adult health providers in Washington.
Other adult health in Spokane
- Jonathan WarrenSpokane$2K
- Keanna WolcottSpokane$1K
- George BaxterSeattle$868K
- April WatkinsSeattle$101K
- Ming Chi HsiaoTacoma$46K
- Leslie SwansonSeattle$18K
- Kindra Clark-SnustadSeattle$10K
- Amanda NortonBellevue$8K
- Alexxia RichmondSnohomish$7K
- Jonathan TurowskiMill Creek$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.